The MACE rate of the regime A and B groups were 8.3% vs 2.7%, (p=0.134) at 1 month and 8.3% vs 5.3%, (p=0.615) at 6 months. Conclusions: Intracoronary bolus-only abciximab, in providing high local drug concentration, achieved similar efficacy and safety outcomes as standard intravenous bolus and infusion abciximab and may be considered a more cost-effective regimen during PPCI.